|
|
 Previous Article | Table of Contents | Next Article 
Prospective comparative trial of autologous versus allogeneic bone marrow
transplantation in patients with non-Hodgkin's lymphoma
V Ratanatharathorn, J Uberti, C Karanes, E Abella, LG Lum, F Momin, G Cummings and LL Sensenbrenner
Division of Hematology, Wayne State University/Detroit Medical Center Bone
Marrow Transplant Program, MI.
A prospective comparative trial of allogeneic versus autologous bone marrow
transplant (BMT) was conducted. Sixty-six consecutive patients (median age,
41; range, 15 to 60; female:male ratio = 21:45) entered this clinical
trial. Priority for allogeneic BMT was given to patients who were 55 or
younger and had a major histocompatibility complex- matched or
1-antigen-disparate sibling donor. Autologous BMT was offered to all other
patients whose age was 60 or younger. Patients who had no sibling donor and
who had BM involvement at the time of evaluation were not eligible.
Thirty-one patients received an allograft, and 35 patients received an
autograft. Thirteen patients received a BM graft purged with
4-hydroperoxycyclophosphamide because of previous BM involvement. Patients
who had previous radiation to the thoracic and/or abdominal areas of more
than 20 Gy received a preparative regimen consisting of cyclophosphamide
(1,800 mg/m2/d for 4 days), VP-16 (200 mg/m2 every 12 hours for 8 doses),
and 1,3-bis(2- chloroethyl)-1-nitrosourea (600 mg/m2 as 1 dose). Other
patients received cyclophosphamide 1,800 mg/m2/d for 4 days followed by
total body irradiation of 12 Gy administered as a single daily fraction
over 4 days. With a median follow-up of 14 months, the progression-free
survival (PFS) for autograft and allograft recipients was 24% +/- 8% (+/-
SE) and 47% +/- 9%, respectively, (P = .21). However, the probability of
disease progression was significantly higher in the autologous group (69%
+/- 9%) than in the allogeneic group (20% +/- 10%; P = .001). When other
confounding prognostic factors were adjusted in the multivariate analysis,
chemosensitive disease and allograft were found to have a significant
favorable influence on probability of disease progression (P = .03 and
.003), but only chemosensitive disease had a significant influence on the
PFS (P < .002). Our results suggest the existence of
graft-versus-lymphoma effect and also support the rationale of using
immunotherapy after autologous BMT. Allogeneic BMT should be preferable to
autologous BMT in younger patients with lymphoma.
Volume 84,
Issue 4,
pp. 1050-1055,
08/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. R. Bishop, R. M. Dean, S. M. Steinberg, J. Odom, S. Z. Pavletic, C. Chow, S. Pittaluga, C. Sportes, N. M. Hardy, J. Gea-Banacloche, et al.
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation
Ann. Onc.,
November 1, 2008;
19(11):
1935 - 1940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schmitz, P. Dreger, B. Glass, and A. Sureda
Allogeneic transplantation in lymphoma: current status
Haematologica,
November 1, 2007;
92(11):
1533 - 1548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Farina and P. Corradini
Current role of allogeneic stem cell transplantation in follicular lymphoma
Haematologica,
May 1, 2007;
92(5):
580 - 582.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-W. Kim, T. E. Tanimoto, N. Hirabayashi, S. Goto, M. Kami, S. Yoshioka, T. Uchida, K. Kishi, Y. Tanaka, A. Kohno, et al.
Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan
Blood,
July 1, 2006;
108(1):
382 - 389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Godal, U. Keilholz, L. Uharek, A. Letsch, A. M. Asemissen, A. Busse, I.-K. Na, E. Thiel, and C. Scheibenbogen
Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2
Blood,
April 15, 2006;
107(8):
3205 - 3211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kami, A. Makimoto, Y. Heike, and Y. Takaue
Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies
Jpn. J. Clin. Oncol.,
December 1, 2004;
34(12):
707 - 716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Corradini, A. Dodero, F. Zallio, D. Caracciolo, M. Casini, M. Bregni, F. Narni, F. Patriarca, M. Boccadoro, F. Benedetti, et al.
Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells
J. Clin. Oncol.,
June 1, 2004;
22(11):
2172 - 2176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Izutsu, Y. Kanda, H. Ohno, H. Sao, H. Ogawa, Y. Miyazaki, K. Kawa, Y. Kodera, S. Kato, Y. Morishima, et al.
Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program
Blood,
March 1, 2004;
103(5):
1955 - 1960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Faulkner, C. Craddock, J. L. Byrne, P. Mahendra, A. P. Haynes, H. G. Prentice, M. Potter, A. Pagliuca, A. Ho, S. Devereux, et al.
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
Blood,
January 15, 2004;
103(2):
428 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Bishop
The Graft-Versus-Lymphoma Effect: Fact, Fiction, or Opportunity?
J. Clin. Oncol.,
October 15, 2003;
21(20):
3713 - 3715.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Bierman, J. W. Sweetenham, F. R. Loberiza Jr, G. Taghipour, H. M. Lazarus, J. D. Rizzo, N. Schmitz, K. van Besien, J. M. Vose, M. Horowitz, et al.
Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkin's Lymphoma: A Comparison With Allogeneic and Autologous Transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation
J. Clin. Oncol.,
October 15, 2003;
21(20):
3744 - 3753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Levine, R. E. Harris, F. R. Loberiza Jr, J. O. Armitage, J. M. Vose, K. Van Besien, H. M. Lazarus, and M. M. Horowitz
A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma
Blood,
April 1, 2003;
101(7):
2476 - 2482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Branson, R. Chopra, P. D. Kottaridis, G. McQuaker, A. Parker, S. Schey, R. K. Chakraverty, C. Craddock, D. W. Milligan, R. Pettengell, et al.
Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies
J. Clin. Oncol.,
October 1, 2002;
20(19):
4022 - 4031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Tabbara, K. Zimmerman, C. Morgan, and Z. Nahleh
Allogeneic Hematopoietic Stem Cell Transplantation: Complications and Results
Arch Intern Med,
July 22, 2002;
162(14):
1558 - 1566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Bertz, G. Illerhaus,, H. Veelken, and J. Finke
Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens
Ann. Onc.,
January 19, 2002;
13(1):
135 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. T. Ho and R. J. Soiffer
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
Blood,
December 1, 2001;
98(12):
3192 - 3204.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Mink and J. O. Armitage
High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma
Oncologist,
June 1, 2001;
6(3):
247 - 256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Carella, M. Cavaliere, E. Lerma, R. Ferrara, L. Tedeschi, A. Romanelli, M. Vinci, G. Pinotti, P. Lambelet, C. Loni, et al.
Autografting Followed by Nonmyeloablative Immunosuppressive Chemotherapy and Allogeneic Peripheral-Blood Hematopoietic Stem-Cell Transplantation as Treatment of Resistant Hodgkin's Disease and Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
December 1, 2000;
18(23):
3918 - 3924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Apostolidis, R. K. Gupta, D. Grenzelias, P. W. M. Johnson, V. I. Pappa, K. E. Summers, A. Salam, K. Adams, A. J. Norton, J. A. L. Amess, et al.
High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up
J. Clin. Oncol.,
February 1, 2000;
18(3):
527 - 527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Freedman, D. Neuberg, P. Mauch, R. J. Soiffer, K. C. Anderson, D. C. Fisher, R. Schlossman, E. P. Alyea, T. Takvorian, H. Jallow, et al.
Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma
Blood,
November 15, 1999;
94(10):
3325 - 3333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. van Besien, K. A. Sobocinski, P. A. Rowlings, S. C. Murphy, J. O. Armitage, M. R. Bishop, O.-k. Chaekal, R. P. Gale, J. P. Klein, H. M. Lazarus, et al.
Allogeneic Bone Marrow Transplantation for Low-Grade Lymphoma
Blood,
September 1, 1998;
92(5):
1832 - 1836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. Verdonck, A. W. Dekker, H. M. Lokhorst, E. J. Petersen, and H. K. Nieuwenhuis
Allogeneic Versus Autologous Bone Marrow Transplantation for Refractory and Recurrent Low-Grade Non-Hodgkin's Lymphoma
Blood,
November 15, 1997;
90(10):
4201 - 4205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Philip, C. Guglielmi, A. Hagenbeek, R. Somers, H. Van Der Lelie, D. Bron, P. Sonneveld, C. Gisselbrecht, J.-Y. Cahn, J.-L. Harousseau, et al.
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
N. Engl. J. Med.,
December 7, 1995;
333(23):
1540 - 1545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
